SecBot SecBot
SECBOTREPLAY Home › Report › NRXP

NRXP · NRx Pharmaceuticals announced an underwritten public offering of common…

NRx Pharmaceuticals, Inc. · PRESS-RELEASE filed Jun 2, 2026 at 16:01 ET

At the news

BEARISHIMPACT 6/10

PRESS-RELEASE filed Jun 2, 2026 at 16:01 ET

NRx Pharmaceuticals announced an underwritten public offering of common stock, with an option for underwriters to purchase an additional 15%. The offering size is undisclosed, and proceeds will be used for working capital and general corporate purposes. This dilutive event comes as a clinical-stage biotech with no approved products, raising capital to fund operations.

  • NRx Pharmaceuticals intends to offer shares of common stock in an underwritten public offering.
  • Underwriter has a 30-day option to purchase up to an additional 15% of shares sold.
  • BTIG, LLC is lead bookrunner; Lucid Capital Markets is joint bookrunning manager.
  • Proceeds will be used for working capital and general corporate purposes.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access